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Abstract
Serology is a core component of the surveillance and management of viral zoon-
oses. Virus neutralization tests are a gold standard serological diagnostic, but re-
quirements for large volumes of serum and high biosafety containment can limit 
widespread use. Here, focusing on Rabies lyssavirus, a globally important zoonosis, 
we developed a pseudotype micro-neutralization rapid fluorescent focus inhibition 
test (pmRFFIT) that overcomes these limitations. Specifically, we adapted an existing 
micro-neutralization test to use a green fluorescent protein-tagged murine leukaemia 
virus pseudotype in lieu of pathogenic rabies virus, reducing the need for specialized 
reagents for antigen detection and enabling use in low-containment laboratories. 
We further used statistical models to generate rapid, quantitative predictions of the 
probability and titre of rabies virus-neutralizing antibodies from microscopic imag-
ing of neutralization outcomes. Using 47 serum samples from domestic dogs with 
neutralizing antibody titres estimated using the fluorescent antibody virus neutrali-
zation test (FAVN), pmRFFIT showed moderate sensitivity (78.79%) and high speci-
ficity (84.62%). Despite small conflicts, titre predictions were correlated across tests 
repeated on different dates both for dog samples (r = 0.93) and in a second data set of 
sera from wild common vampire bats (r = 0.72, N = 41), indicating repeatability. Our 
test uses a starting volume of 3.5 µl of serum, estimates titres from a single dilution 
of serum rather than requiring multiple dilutions and end point titration, and may be 
adapted to target neutralizing antibodies against alternative lyssavirus species. The 
pmRFFIT enables high-throughput detection of rabies virus-neutralizing antibodies 
in low-biocontainment settings and is suited to studies in wild or captive animals 
where large serum volumes cannot be obtained.
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1  | INTRODUC TION
The last few decades have seen a surge in newly emerging human vi-
ruses that originate from wildlife (Cunningham et al., 2017; Daszak 
et al., 2000; Goodin et al., 2018). Key examples include Nipah virus 
(Gurley et al., 2017), Seoul virus (Kerins et al., 2018), 2009 H1N1 
(Mena et al., 2016) and the recent SARS-CoV-2 (Zhou et al., 2020). 
Understanding the epidemiological dynamics of such viruses 
within their natural host populations is a fundamental component 
to discerning the spatiotemporal dynamics of past outbreaks and 
anticipating future emergence (Cunningham et al., 2017; Plowright 
et al., 2016). Investigating the dynamics of zoonotic viruses within 
wildlife presents multiple challenges such as limited sample sizes, 
biased sampling and multiple diagnostic tests that are difficult to 
compare. Moreover, viruses themselves may be undetectable at 
the moment of sampling when infectious periods are short or virus 
shedding is intermittent (Becker et al., 2019; Gilbert et al., 2013; 
Plowright et al., 2019). Consequently, key parameters needed to 
inform population-level disease dynamics (e.g., incidence, infec-
tion and incubation periods) are difficult or impossible to measure 
directly (Borremans et al., 2016). Serological tests offer a powerful 
alternative to approaches that rely on pathogen detection (Gilbert 
et al., 2013). Since pathogen-specific antibodies generally persist 
longer than the pathogen itself, serological data can inform indi-
vidual exposure histories and population seroprevalence and, in 
some cases, help approximate the force of infection (Borremans 
et al., 2016; Gamble et al., 2020; Gilbert et al., 2013; Metcalf 
et al., 2016). However, applying serology to longitudinal studies 
of wildlife presents distinct challenges from tests used in clinical 
diagnostic settings, where accuracy takes precedence over scal-
ability. In particular, serological tests for studies of wildlife should 
be amenable to the small volumes of serum that often character-
ize collections from small-bodied hosts (e.g., rodents, bats, birds), 
scalable to large numbers of samples required for such studies, 
and possible to implement in low-biocontainment laboratories.
Rabies lyssavirus (RV; Genus Lyssavirus, Family Rhabdoviridae) is 
a zoonotic virus transmitted in saliva by the bite of infected mam-
mals (mainly Carnivora and Chiroptera) (Rupprecht et al., 2017). 
RV constitutes a substantial global health problem that is respon-
sible for over 59,000 human fatalities annually, mostly attributable 
to domestic dogs (WHO, 2017). In Latin America, vampire bat RV 
causes more cases of human and domestic animal rabies mortality 
than RV transmitted by dogs. Similarly, bats are consistently among 
the most frequent sources of human rabies exposure in the United 
States (Ma et al., 2020; Schneider et al., 2009). Bat lyssaviruses ex-
emplify the challenges of studying zoonoses using pathogen detec-
tion and the potential advantages of serological inference (Turmelle 
et al., 2010). Active infections are rarely detected due to low popu-
lation-level incidence and the short infectious period that precedes 
death (Jackson et al., 2008; Turmelle et al., 2010). However, abortive 
infections (i.e., bats that are exposed to RV but do not become in-
fectious) are routinely observed through antibody presence in ap-
parently healthy bats (Constantine et al., 1968; Jackson et al., 2008; 
Obregón-Morales et al., 2017; Steece & Altenbach, 1989). As 
such, antibody detection is commonly used for ecological and ep-
idemiological studies of bat rabies (Blackwood et al., 2013; Costa 
et al., 2013; de Thoisy et al., 2016; George et al., 2011; Horton 
et al., 2020; Streicker et al., 2012; Wright et al., 2010).
Existing tests to detect RV antibodies include enzyme-linked 
immunosorbent assays (ELISAs) (Barton & Campbell, 1988; Cliquet 
et al., 2004; Wasniewski & Cliquet, 2012) and virus neutralization 
tests (Cliquet et al., 1998; Smith et al., 1973). ELISAs are a rapid and 
effective method for testing large numbers of samples, but they do 
not detect virus neutralization (Ma et al., 2012; Welch et al., 2009). 
Moreover, since ELISAs ideally require a secondary antibody spe-
cific to the host species of the original sample (Reynes et al., 2004), 
which is often non-existent, they are not widely used in wildlife 
rabies surveillance. Tests detecting virus-neutralizing antibodies 
(VNAs) are more commonly adopted (De Benedictis et al., 2012; Irie 
& Kawai, 2002; Moore & Hanlon, 2010). Specifically, the fluorescent 
antibody virus neutralization test (FAVN) and the rapid fluorescent 
focus inhibition test (RFFIT) are considered the gold standard for 
measuring vaccination response by the World Health Organization 
(WHO) (Briggs et al., 1998; De Benedictis et al., 2012). Both the 
FAVN and RFFIT have been modified to facilitate use with wildlife 
samples. For instance, Kuzmin et al. (2008) modified the RFFIT into a 
micro-neutralization test using 4-well Teflon-coated slides instead of 
8-well chamber slides. This produced a sensitive and specific test that 
only required 3.5 µl of serum (regular RFFIT and FAVN require ~50 
μl of serum) (Kuzmin et al., 2008). Several other laboratories have 
introduced the modification of pseudotype viruses (i.e., non-rabies 
viruses engineered to express heterologous envelope glycopro-
teins) to quantify VNA titres without highly pathogenic live lyssa-
viruses (Temperton et al., 2015), which in most countries involves 
biosafety-level (BSL)-3 laboratories to produce concentrated virus 
stocks (WHO, 2018). Pseudotyped viruses based on vesicular sto-
matitis virus (Moeschler et al., 2016), human immunodeficiency virus 
and murine leukaemia virus (MLV) (Wright et al., 2008) tend to be 
highly sensitive and specific relative to live lyssavirus counterparts. 
Viral pseudotypes have also been modified to incorporate molecu-
lar biomarkers such as firefly luciferase, renilla luciferase or green 
fluorescent protein (GFP), eliminating the need to fix and stain cells 
with a fluorescein isothiocyanate (FITC)-conjugated rabies antibody, 
which reduces test cost (Bentley et al., 2015; Mather et al., 2013; 
Moeschler et al., 2016; Moore & Hanlon, 2010; Wright et al., 2008).
Despite these improvements, existing variations of RV neutral-
ization tests have several limitations. First, all tests require serial di-
lutions of serum samples, each of which requires manual microscope 
scoring that increases personnel time and risks of error (Moeschler 
et al., 2016; Péharpré et al., 1999). Second, testing is commonly split 
into screening and end point titration phases, requiring tests to be 
run in duplicate or sequentially. Third, pseudotypes have not yet 
been integrated into micro-neutralization tests, implying that tests 
to detect VNAs against most lyssaviruses in their natural bat reser-
voirs can only be carried out in BSL-3 or higher facilities. The grow-
ing demand to study wildlife on large spatial and temporal scales 
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would benefit from minimizing these logistical constraints (Becker 
et al., 2019).
The ideal serological diagnostic would be a scalable virus neu-
tralization test that requires low-volume samples and can be car-
ried out in any standard microbiology/cell culture laboratory. Here, 
the micro-neutralization RFFIT is adapted to use an MLV-based viral 
pseudotype bearing the RV glycoprotein and carrying a GFP marker 
gene. Further, we introduce a novel quantitative approach that com-
bines digital image analysis of infected cells with statistical analy-
sis, which allows us to estimate rabies virus-neutralizing antibody 
(RVNA) titres without multiple serum dilutions or rounds of testing. 
Our approach relies on the expectation of a negative relationship 
between RVNA concentrations in serum and the number of cells that 
become infected upon viral challenge in the presence of that serum. 
Defining that relationship quantitatively using known titres of stan-
dard rabies immune globulin (SRIG) allows predicting the presence 
and, when appropriate, titres of RVNAs in test sera. Our approach, 
which we refer to as a pseudotype micro-neutralization RFFIT (here-
after, pmRFFIT, Figure 1), provides a safe, low-cost alternative to 
standard RV neutralization tests that is suitable for large-scale, pop-





For all the neutralization tests, mouse neuroblastoma cells N2A 
(Neuro-2A, ATCC® CCL131™) were cultured in Minimum Essential 
F I G U R E  1   Workflow of the pmRFFIT approach. (a) Set-up of the neutralization test using an MLV(RG) pseudotype and 2 dilutions of 
either SRIG or animal serum. (b) Microscopy phase and imaging to perform the cell count of the fluorescent cells to construct a database to 
fit the statistical models. (c) Construction of the statistical models with two different types of prediction
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Media (MEM) supplemented with 10% foetal bovine serum (FBS), 1% 
100× non-essential amino acid (NEAA), 1% 200mM L-glutamine and 
1% antibiotic–antimycotic. For viral pseudotype production, human 
embryonic kidney 293T cells (293T, ATCC® CRL-3216™) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% FBS, 1% 200 mM L-glutamine, 100 units/ml penicillin, 
1 µg/ml streptomycin and 400 µg/ml G418 (Geneticin) antibiotic.
2.1.2 | Pseudotype production
MLV pseudotypes expressing the challenge virus standard-11 
(CVS-11) rabies virus glycoprotein (MLV(RG)) were generated by 
co-transfection of pCMVi (MLV gag-pol expression vector), pCNCG 
(MLV viral origin and GFP reporter gene) and pI.18-CVS-11 (plasmid 
encoding the CVS-11 RG) (Bock et al., 2000; Towers et al., 2000; 
Wright et al., 2008). Plasmids were transfected using polyethyl-
enimine (Polysciences, Inc.) into 293T cells at a ratio of 1:1.5:1 of 
pCMVi/pCNCG/pl.18-CVS-11. After 72 hr, the supernatant contain-
ing the viral pseudotypes was harvested, aliquoted and stored at 
−80°C until further use. Virus concentration was determined in N2A 
cells by calculating the TCID50 (50% tissue culture infective dose) 
using the end point method and using the Spearman–Kärber formula 
(Condit, 2001; Hierholzer & Killington, 1996).
2.1.3 | Neutralization test
A two-dilution micro-neutralization test was established follow-
ing Kuzmin et al. (2008); however, in place of 4-well Teflon-coated 
slides, 6-well Teflon-coated slides (Tekdon Inc.) were used, enabling 
3 samples to be analysed per slide. Each serum sample (starting vol-
ume of 3.5 µl) was screened at a 1:10 and 1:25 dilution (a total of 2 
wells per sample). Serum dilutions were inoculated with 12.5 µl of 
MLV(RG) (viral input: 300–400 TCID50) and incubated in humidified 
square petri dishes at 37°C, 5% CO2 for 90 min. After incubation, 
25 µl of N2A cells (2 × 106 cells/ml) was added to the serum–virus 
mixture and slides were incubated at 37°C, 5% CO2 for 66 to 72 hr 
in the humidified square petri dishes. This extended incubation pe-
riod (compared to the FAVN (48 hr) or the RFFIT (20 to 24 hr)) was 
required for the MLV(RG) to generate sufficient GFP expression for 
later microscopy. Since our pseudotype virus used GFP to indicate 
viral entry into cells, neither acetone fixation nor staining with anti-
rabies monoclonal globulin was required. Every neutralization test 
included three internal controls: (1) a cell-only control where no 
viral pseudotype or serum was added to the well; (2) a viral pseudo-
type control, comprising back titrations of the MLV(RG) with (a) the 
original viral pseudotype concentration (300–400 TCID50), (b) a 1:10 
dilution and (c) a 1:100 dilution; and (3) a negative control for neu-
tralization that included two wells with 300–400 TCID50 of MLV(RG) 
without any serum. A standard curve was generated with each neu-
tralization test describing the expected number of infected cells ver-
sus titre concentration. For this, the same protocol was used with 
six different titre concentrations of SRIG in lieu of serum samples: 
0.01, 0.025, 0.05, 0.1, 0.15 and 0.2 IU/ml (reconstituted at 30 IU/ml 
in 1.0 ml of nuclease-free water, 2nd WHO International Standard, 
Human; NIBSC, UK) (Figure 1a).
2.1.4 | Imaging and data processing
After incubation, slides were photographed at 4× magnification 
under a fluorescence microscope (EVOS FL Cell Imaging System). 
As representative images of the whole well, five equally sized fields 
(four corners and centre) were selected and photographed clockwise 
from the top left corner, such that the fifth photograph was always 
the centre field. Each photograph was processed through the freely 
available software, ImageJ (version 1.52k (Rasband, 2018)) using the 
Autolocal Threshold Phansalkar plugin (size radius 15) (part of the Fiji 
distribution (Schindelin et al., 2012)). Each image was transformed 
into a binary representation (every pixel stored as a single bit), indi-
cating the presence (white) and absence (black in the background) of 
GFP fluorescence. Next, the command “Analyze Particles” was used 
to count the total number of fluorescent cells per field (i.e., infected 
cells). This command grouped and counted the white neighbouring 
pixels with a pre-determined size area and circularity to be a single 
cell (size area: 5–50 circularity: 0.80–1.0), so counts corresponded 
to the number of infected cells. Cell count outputs were converted 
into a standardized spreadsheet using a Python version 3.7.2 script 
(Python Core Team, 2019) (script available in supplementary infor-
mation). At the end of the image processing step, each serum sam-
ple was described by 10 data points consisting of the number of the 
fluorescent cells in each of 5 fields (photographs) in the 1:10 and 
1:25 dilutions (Figure 1b).
2.2 | Statistical analysis
All statistical analyses were executed in R (R Core Team, 2020). 
To predict the probability of RVNA presence, a generalized linear 
mixed model (GLMM) with a binomial distribution was fit to the bi-
nary outcome of the cell counts from the SRIG concentration series. 
Titres ≤ 0.1 IU/ml were considered RVNA-negative and > 0.1 IU/ml 
were considered RVNA-positive. Other serology studies in wildlife 
have used similar thresholds to detect RVNA (Araujo et al., 2014; 
Campos et al., 2019; Marcelo Azevedo de Paula Antunes et al., 2017; 
Silva et al., 2010). To predict RVNA titres, a GLMM with a log-normal 
distribution was fit to the infected cell counts across the SRIG con-
centration series. For both the binomial and log-normal models, a 
model was constructed including all data (i.e., from the 1:10 and 1:25 
dilutions). For this model, two fixed effects were considered: (1) the 
count of virus-infected N2A cells (scaled to improve model conver-
gence) and (2) the serum dilution level (two factors: 1:10 and 1:25 
dilution). Random slope and intercept terms were considered for the 
date the test was run (“test date”) to account for observed varia-
tion in the relationships between SRIG titres and infected cell counts 
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across dates (Figure 2). A random slope term was also considered 
for the field number (1 to 5) within each microscope well (“field”) 
to account for variation in cell counts between fields (the middle 
field, field 5, had more agglomerated cells in particular). To evaluate 
whether a simpler, single dilution test produced comparable results, 
the full data set was then subset to the 1:10 dilution only. The bino-
mial and log-normal models fit to this data subset included only the 
fixed effect of the virus-infected N2A cell counts, but the random 
effects were identical to those explained above (i.e., test date and 
field). Models were fit using the lme4 package (Bates et al., 2015). 
The predict function was used to generate the predicted probability 
that a SRIG concentration or serum sample was seropositive (bino-
mial model) and its corresponding RVNA titre (log-normal model). 
Predictions per field were averaged to obtain results per sample 
(Figure 1c).
2.2.1 | Model selection
To select the best-performing models, a top-down model selection 
strategy was implemented (Zuur et al., 2009). First, we identified the 
optimal random effects by comparing models with alternative ran-
dom-effect structures, but the same fixed effects, using the Akaike 
information criterion corrected for small sample size (AICc). This was 
calculated using the MuMIn package (Bartoń, 2020). A lower AICc 
with a difference of at least two values (ΔAICc > 2) was considered 
as evidence of improved model fit. Next, keeping the chosen ran-
dom effects, models with the two different data sets were evalu-
ated (simpler model: 1:10 data set, and more complex model: 1:10 
and 1:25 data set) (Table 1). Since models fit to different data sets 
cannot be compared through AICc, the simpler and more complex 
models were compared using predictions for SRIG (sera with known 
titres). For the binomial models, the sensitivity and specificity with 
a threshold of > 0.1 IU/ml for seropositivity were used. For the log-
normal models, the Spearman correlation coefficients of predicted 
and known SRIG titres were compared.
2.2.2 | Validation of the pmRFFIT
To understand the variability of the pmRFFIT, replicate SRIG titre 
concentration curves were produced on 6 different dates between 
30/05/2019 and 27/06/2019 (hereafter “Test 1” through “Test 6”). 
We evaluated dispersion in the counts (and hence potential predic-
tive power) for the 1:10 versus the 1:25 dilution series of different 
SRIG concentrations by calculating the interquartile range (IQR) of 
the infected cell count.
Dog (N = 47) and bat (N = 41) sera were used to assess pmRFFIT 
repeatability. Dog sera had previously been tested using FAVN at 
the Animal Health and Veterinary Laboratories Agency, Weybridge 
(Wright et al., 2009). Bat sera were collected from common vampire 
bats (Desmodus rotundus) as part of an ongoing field study in Peru 
(collection permit: 0142–2015 SERFOR/DGGSPFFS; exportation 
permit: 003327-SERFOR). Specific and individual sample informa-
tion is available in the supplementary information (SI, Table S1).
To quantify repeatability, dog and bat sera were processed 
using the pmRFFIT as described above on two separate dates. For 
the binomial model, repeatability was measured as the proportion 
of samples with the same predicted serological status on both test 
dates. For the log-normal model, repeatability was calculated as the 
Spearman correlation coefficient of predicted RVNA titres from dif-
ferent test dates.
We measured the accuracy of the pmRFFIT as the overall propor-
tion of positive and negative samples correctly detected relative to 
F I G U R E  2   Raw counts of fluorescent 
cells for the SRIG concentration curves 
from 6 different pmRFFIT from different 
test dates and for each dilution. The 
dilutions were performed on the same 
date, with one well next to the other. Each 
colour represents a different test date. 
The loess curves denote differences in the 
counts from test to test
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the FAVN, using binomial predictions from dog sera. The same data 
were used to estimate the sensitivity (accurately predicted positive/
(accurately predicted positive + inaccurately predicted negative)) and 
specificity (accurately predicted negative/(accurately predicted neg-
ative + inaccurately predicted positive)) of the pmRFFIT. Sera with 
FAVN titres > 0.1 IU/ml were classified as positive and ≤ 0.1IU/ml as 
negative. Only data from the first pmRFFIT test date were used under 
the assumption that future applications would preferably use a single 
test. To compare pmRFFIT accuracy in different FAVN titre ranges, the 
RVNA values obtained through FAVN were categorized through the 
cut function in R. The number of categories was obtained by dividing 
the range of the RVNA titre values (maximum minus minimum value 
obtained through FAVN) by the optimal category width, calculated 
with the Freedman–Diaconis rule (Freedman & Diaconis, 1981).
Model Random effects AICc ΔAICc W
B 1. Test date as random intercept and 
random slope
91.62 0.0 0.71
2. Test date as random intercept and 
random slope + number of field as 
random intercept
93.49 1.87 0.28
3. Test date as random intercept 102.32 10.70 0.0
4. Test date as random 
intercept + number of field as random 
intercept
104.28 12.66 0.0
L 1. Test date as random intercept and 
random slope + number of field as 
random intercept
−1746.59 0.0 0.7
2. Test date as random intercept and 
random slope
−1744.89 1.70 0.3
3. Test date as random 
intercept + number of field as random 
intercept
−1637.32 109.27 0.0
4. Test date as random intercept −1637.30 109.29 0.0
TA B L E  1   Random-effect structures 
investigated for the binomial (B) and 
log-normal (L) models, and respective 
model fit measures: AICc, difference in 
AICc from best model (ΔAICc) and weight 
(W). The fixed effects for all these models 
were identical and included the scaled 
count of the fluorescent cells and the 
dilution effect
F I G U R E  3   Results of the models fit to the SRIG control data. All graphs compare the one-dilution (1:10) and the two-dilution (1:10 
and 1:25) models. (a) Model fit of the titres of the SRIG concentration curve versus the predicted probability from the binomial model. 
The horizontal dash line represents the 95% probability, and the vertical dash line represents the previously set threshold at 0.1 IU/ml. 
(b) Sensitivity and specificity of the binomial prediction per test date. (c) Correlation of the titres of the observed SRIG values versus the 
predicted values with the log-normal models. (d) Comparison of the Spearman coefficients between the correlations of the observed titres 
versus the predicted titres per test date
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We later re-evaluated accuracy for weak positives using only 
the lowest titre FAVN samples. Since we designed the pmRFFIT 
to quantify low RVNA titres and many of the available dog sera 
had RVNA titres above the range of our test, direct comparison of 
continuous titre predictions for the whole range was not feasible. 
Instead, we compared predicted pmRFFIT titres using the relevant 
FAVN range (0–0.22 IU/ml). To evaluate the sensitivity and spec-
ificity of different threshold values in the log-normal predictions, 
we applied a receiver operating characteristic (ROC) curve analy-
sis. The ROC curve was produced across all the range of evaluated 
titres, using a threshold of > 0.1 IU/ml (positives) as the bench-
mark reference.
3  | RESULTS
We assessed the variability of the pmRFFIT using the SRIG titre 
concentration curves generated in 6 different dates (“Test 1” 
through “Test 6”). As expected, the number of infected cells de-
clined at higher SRIG titres in all replicates; however, the shape 
of the antibody decay curve varied across test dates (Figure 2). At 
the 0.1 IU/ml SRIG concentration, infected cell counts were more 
dispersed in the 1:25 dilution than in the 1:10 dilution, as indicated 
by higher IQR within each of the 6 test dates. Across all the SRIG 
concentrations in all test dates (N = 36), 77.78% of the count com-
parisons were less dispersed in the 1:10 dilution suggesting this 
dilution could be more precise for downstream statistical analysis 
(SI, Figure S2).
3.1 | Prediction of seropositivity using 
binomial GLMM
Binomial GLMMs accurately predicted seropositive and seronega-
tive SRIG concentrations (Figure 3). The best random effects for 
the binomial model included a random slope and intercept for test 
date (Table 1). The models built with the 1:10 dilution data only 
(“one-dilution model”) and from both the 1:10 and 1:25 dilution 
data (“two-dilution model”) had equivalent specificity (100%), but 
the one-dilution model was more sensitive (100% versus 58.33%, 
Figure 3a,b). Furthermore, the two-dilution binomial model failed 
to correctly predict the seropositive controls on 4 out of the 6 test 
dates, confirming improved performance of the one-dilution model 
(Figure 3b).
3.2 | Prediction of titre values using log-
normal GLMM
The log-normal GLMMs accurately predicted RVNA titres from the 
data sets generated through our protocol on different test dates 
(Figure 3). The best log-normal model included a random intercept 
and slope for test date. Although the most complex model had the 
lowest AICc, the simpler model (without the random intercept of 
field) had a ΔAICc < 2 (Table 1). Observed and predicted SRIG titres 
were highly correlated for both the one- and two-dilution models 
(r = 0.95, Figure 3c). When comparing test dates (i.e., one-to-one 
comparison between correlations of the one-dilution and the two-
dilution model from the same test dates), the correlation coefficients 
were similar, suggesting the simpler one-dilution model is sufficient 
for titre prediction (Figure 3d).
3.3 | Repeatability, accuracy, sensitivity and 
specificity with animal sera
Among all the animal serum samples (N = 88), 95.45% were con-
sistently predicted as seropositive or seronegative (92.68% for bats 
and 97.87% for dogs). Bat samples (N = 41) had a repeatability of 
66.7% for positive samples (6/9 positive samples were positive in the 
second round) and 100% for negative samples (N = 32). Dog sam-
ples (N = 47) had 100% repeatability for positive samples (N = 28) 
and 94.74% for negative samples (18/19 negative samples remained 
negative in the second round) (Figure 4a, SI, Figure S4). Predicted 
titres between test repetitions were correlated for both sera (both 
r = 0.81, bat r = 0.72, dog r = 0.93, Figure 4b).
Relative to FAVN, pmRFFIT predictions using the binomial 
model on dog sera showed overall moderate accuracy (80.43% 
F I G U R E  4   Repeatability of the 
predictions in bat (N = 41) and dog 
(N = 47) samples. (a) Percentage of 
repeatability of the seropositive outcome 
of the bat and dog serum samples with 
the pmRFFIT test. (b) Linear correlation 
of the predicted titres between the first 
and second tests for dog serum and 
bat serum. Diamonds indicate samples 
that were contradictory in the binomial 
prediction
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of samples in agreement with FAVN; sensitivity = 78.79%; spec-
ificity = 84.62%). Dog samples categorized as positive according 
to the binomial prediction (N = 28) had a higher correct predic-
tion. Only 2 positive samples failed in the pmRFFIT prediction 
compared to the FAVN. For dog samples categorized as negative 
by the binomial pmRFFIT (N = 9), 7 samples were contradictory. 
These misclassified samples were consistently predicted as neg-
ative in the pmRFFIT, and titres displayed a strong correlation 
between tests (r = 0.93, SI, Table S3). The binomial model was 
most accurate for samples with high RVNA titres (>1.04 IU/ml, 
N = 13; 100% predicted to be seropositive; Figure 5a). At lower 
FAVN titres (<1.04 IU/ml, N = 33), 72.73% of samples were pre-
dicted correctly by the pmRFFIT. To evaluate the accuracy of 
the binomial prediction in this lower range, the titre categoriza-
tion process was repeated using the subset of data with FAVN 
titres ≤ 0.871 IU/ml (N = 33). Among the higher titre samples 
in this particular set (>0.27 to ≤ 0.871 IU/ml, N = 11), 90.91% 
were correctly predicted as seropositive (Figure 5b). From the 
samples with titres ≤ 0.27 IU/ml, only 63.64% were correctly 
predicted (N = 22, Figure 5b). Accuracy rose to 83.33% in the 
lowest FAVN titre range (≤0.07 IU/ml, N = 12). The pmRFFIT ti-
tres from the log-normal prediction were correlated with FAVN 
titres (r = 0.51–0.85, depending on the data subset, SI Figure S3). 
The ROC curve relative to the FAVN titre values showed that 
threshold values around 0.166 IU/ml maximized sensitivity and 
specificity.
4  | DISCUSSION
The most commonly applied serological tests to detect RVNA titres 
challenge a range of serial dilutions of serum with infectious RV. 
This process is labour-intensive and requires laboratory capacity to 
grow large quantities of pathogenic RV. Here, we provide an alterna-
tive serological framework that uses a combination of digital image 
analysis and statistical analysis to estimate the presence and titre of 
RVNA from a single dilution using only 3.5 µl of serum.
The pmRFFIT differs from other lyssavirus neutralization tests in 
several key aspects. It uses an MLV(RG) pseudotype rather than patho-
genic RV, allowing the pmRFFIT to be performed in any low-contain-
ment laboratory with appropriate cell culture and microscopy facilities. 
The addition of GFP expression is significant, since it removes the 
need for FITC-conjugated antibody (reducing reagent costs) and the 
fixation and staining steps used in traditional RFFIT or FAVN. One po-
tential drawback of using GFP expression to measure infectivity is the 
prolonged neutralization period (66-hr versus 24-hr RFFIT and 48-hr 
FAVN) required to gain sufficient fluorescence for image processing 
(Aubert, 1992; Smith et al., 1973). Longer neutralization requirements 
(60 hr) were also required in a FAVN modification using a GFP express-
ing recombinant CVS-11-eGFP but did not alter results relative to the 
test run with CVS-11 (Xue et al., 2014). Fortunately, extended incu-
bations are unlikely to alter neutralization outcomes since MLV(RG) 
pseudotype is replication incompetent. This prevents infection of ad-
ditional cells during incubation (Temperton et al., 2015).
F I G U R E  5   Validation of pmRFFIT 
with the FAVN on the dog serum 
samples. (a) Seropositivity comparison 
for all FAVN titres: sensitivity = 78.79%; 
specificity = 85.71%; overall 
accuracy = 80.85% (N = 47). (b) 
Seropositive comparison of lower FAVN 
titres: overall accuracy = 72.73% (N = 33). 
(c) ROC curve of the log-normal titre 
prediction of the first test compared to 
the FAVN at threshold > 0.1 IU/ml for 
seropositivity. The continuous thresholds 
for the pmRFFIT are in green
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The pmRFFIT also uses an imaging pipeline that combines sys-
tematic photography of microscope fields with automated digital 
image processing to count infected cells. Microscopy in neutralization 
tests is time-consuming and presents challenges for interlaboratory 
comparisons due to multiple sources of variation, especially those 
that affect the manual readout (e.g., laboratory user, manual pipet-
ting, uneven cell monolayer) (Briggs et al., 1998; Cliquet et al., 1998; 
Eschbaumer et al., 2014; Péharpré et al., 1999; Timiryasova 
et al., 2019). The pmRFFIT standardized approach minimizes these 
sources of error while potentially reducing microscope operator time. 
Moreover, the imaging process generates traceable and permanent 
electronic records of the raw data, eliminating the need to manually 
digitize records of field counts. Several investigators have previously 
incorporated image processing into RV neutralization tests. For ex-
ample, Pérhapré et al. (1999) modified the FAVN and RFFIT readout 
by using an automated image analysis; however, one important draw-
back was the high cost of the equipment (a motorized stage and the 
software required for this). The pmRFFIT uses freely available image 
processing program and plugins (ImageJ) making the approach acces-
sible for any user. Streicker et al. (2012) also used photography and 
image processing to count pixels using a microRFFIT but did not make 
full use of the quantitative nature of imaging data to obtain RVNA 
titres and used pathogenic RV rather than a viral pseudotype. Finally, 
instead of scoring microscope fields or wells as virus positive or neg-
ative across many dilutions to obtain serological status and titre, the 
pmRFFIT achieves this by quantifying levels of cellular infection in 
a single serum dilution. The efficacy of this statistical modelling ap-
proach highlights the value of historically underutilized quantitative 
data on cellular infectivity for lyssavirus serology.
Model selection indicated substantial day-to-day variation in the 
SRIG dilution series. This effect was unsurprising since virus neutral-
ization tests are biologically dynamic systems that can be influenced 
by many factors (e.g., variability in the humidity of the incubator, 
technical manipulation, light condition of the microscope, variabil-
ity in GFP expression in the cells) (Briggs et al., 1998; Hammami 
et al., 1999; Kostense et al., 2012). Since our statistical approach 
handles this variability through the random effect of test date, the 
pmRFFIT is best suited for large numbers of serum samples that 
require testing to be carried out across multiple batches. However, 
performance is only marginally reduced when running single models 
for each test date, implying the pmRFFIT may still be useful when 
fewer samples are available for testing (see SI, Figures S4 and S5). 
Surprisingly, fitting the GLMMs to data from a single 1:10 dilution of 
SRIG predicted both seropositivity and RVNA titre more accurately 
than models fit to both the 1:10 and 1:25 dilutions. The reduced 
performance of the two-dilution model reflected higher variability 
in the 1:25 dilution compared to the 1:10 dilution, as evidenced by 
greater IQR values (SI, Figure S2). Ultimately, this variability likely 
reflects both higher stochasticity in infected cell counts at lower 
serum concentrations and pipetting error. Regardless, the ability to 
detect low titres (<0.2 IU/ml) with just one dilution and without the 
need to conduct separate tests for screening and titration is advan-
tageous since manual effort and materials are reduced.
Cell-based experiments are expected to be more variable than 
other serological diagnostics, and often the allowed variation for 
test precision is up to 30% (Kostense et al., 2012; Timiryasova 
et al., 2019). For example, Kostense et al. (2012) evaluated RFFIT 
repeatability by testing 3 different types of immunoglobulins (HRIG, 
CL184 and SRIG), and intratest variation was 26%, 18% and 25%, 
respectively. Similarly, Timiryasova et al. (2019) validated a RFFIT 
protocol with 15.7% variation among intratest repetitions. In com-
parison, our test showed higher repeatability for serum samples 
from dogs. Repeatability was slightly lower in bat samples; however, 
two out of the 3 conflicting bat samples were explainable as thresh-
old effects. Specifically, predicted titres in both tests occurred near 
the threshold defining seropositivity and varied by < 0.05 IU/mL be-
tween test replicates, indicating only trivial variation between tests 
(Figure 4b, SI, Table S2). Nevertheless, quantitative titre predictions 
across replicate runs were less consistent in bat samples relative to 
dogs (Figure 4b). One explanation for this finding could be linked to 
serum quality in bat samples arising from the collection of whole 
blood using peripheral venipuncture and capillary collection, rather 
than cephalic or jugular venipuncture used for dog samples. Higher 
haemolysis levels in bat samples could have increased variation in 
test outcomes (Neumann & Bonistalli, 2009). As a second possibility, 
predictions of lower titres tended to have a higher variability and 
titres in bats were on average lower than dogs, many of which were 
previously vaccinated. Indeed, 26 out of 47 dogs compared to 5 out 
of 41 bat samples had predicted titres ≥ 0.15 IU/ml. Consistent with 
our findings, Kostenze et al. (2012) also detected that the RFFIT had 
prediction limitations at lower titre levels (limit of quantification: 
0.2 IU/ml, limit of detection: 0.118 IU/ml). Moreover, they observed 
antibody concentration curves had an initial and evident bend in 
the titre concentration at 0.2 IU/ml, but the ability to observe slope 
changes in the lowest concentrations of serum (<0.1 IU/ml) was 
challenging. Overall, the pmRFFIT was most precise in discriminat-
ing strong positives from strong negatives, where the highest and 
lowest titres were constantly predicted as such. In consideration of 
these points, standard serological methods might have limitations 
measuring low RVNA titres (<0.5 IU/ml), while the pmRFFIT grants a 
highly repeatable approach for these titre values.
Using the external validation set of dog samples with known 
RVNA titres, the overall accuracy of the pmRFFIT was moderately 
high (Figure 5). The pmRFFIT was also able to estimate RVNA titres 
from a single serum dilution which correlated with known FAVN titres 
(SI Figure S3). Discrepancies occurred in samples with FAVN titres 
ranging from 0.07 to 0.29 IU/ml but were not observed for samples 
with higher titres (N = 23). In the previous analysis of these samples, 
sera that did not reach the 0.5 IU/ml threshold were considered neg-
ative and were not re-tested (Wright et al., 2009). We therefore can-
not disregard the possibility of inaccurate titre assessment through 
FAVN, considering low-titre detection is even more challenging 
through classical approaches and that titre prediction through FAVN 
tests can vary even for higher titres (i.e., samples scoring 0.5 IU/ml 
can range from 0.38 to 0.66 IU/ml when repeated) (Liu et al., 2012; 
Wright et al., 2009). Although we did not carry out a formal validation 
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for the bat samples, the estimated seroprevalence was 0.21 (CI: 0.09, 
0.35), consistent with several previous studies using the RFFIT (de 
Thoisy et al., 2016; Steece & Altenbach, 1989; Streicker et al., 2012, 
2013). Nevertheless, the ability of our approach to estimate RVNA 
titres for all samples tested without additional laboratory work pro-
vides an additional layer of information. The titre continuous levels 
can be further used to gauge confidence in positive or negative pre-
dictions. For example, predicted titres abutting the threshold for se-
ropositivity might be viewed with caution.
Selecting a different threshold (i.e., 0.166 from the ROC curve) 
would have increased the assessment values of the pmRFFIT (e.g., 
repeatability in bats) but would have predicted low-titre sera as 
negative. Detection of low RVNA titres is important for epidemio-
logical studies of rabies exposure (Gold et al., 2020). For example, 
bats sometimes produce low levels of RVNA after viral exposures, 
and the antibody response can wane to undetectable levels within 
months after the first exposure (Jackson et al., 2008; Turmelle 
et al., 2010). Indeed, the predicted titres among our predicted se-
ropositive bat samples were consistently less than < 0.12 IU/ml. 
For this reason, we designed our test to detect low RVNA titres, 
with seropositivity defined as > 0.1 IU/ml. The ROC analysis for 
the dog sera showed this was close to the optimal range of thresh-
olds for sensitivity and specificity. Titres > 0.2 IU/ml, as might be 
required for studies concerned with protective levels following 
immunization, cannot currently be estimated accurately. Using 
pmRFFIT, such samples would be classified as seropositive with 
a predicted titre of 0.2 IU/ml. If desired, studies aiming to pre-
dict RVNA titres higher than the focus of this study would require 
higher additional serum dilutions in conjunction with a greater 
range of SRIG concentrations.
In summary, the pmRFFIT quantifies RVNA titres using a single, 
low-biocontainment test that requires only a single dilution of test 
sera. We recommend first employing the binomial model at a pre-de-
termined threshold for seropositivity and then using the log-normal 
model to predict titres for the putatively positive samples (considered 
positive by the binomial model). If benchmark data are available, it 
would be possible to select the most sensitive and specific threshold 
after predicting titres for all available samples using the ROC curve 
analysis. Downstream analyses could use binomial and continuous 
data as needed for specific project objectives. The pmRFFIT could be 
extended to other lyssaviruses for similarly low-biocontainment test-
ing of neutralizing antibodies. The ability to perform the test using the 
low-volume sera that are often available for studies of wild bats or 
longitudinal studies of captive bats is a particularly useful feature of 
our approach. Such studies are increasingly desirable to investigate 
the transmission dynamics of poorly understood bat viruses.
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